CNK Cell Therapeutics

CNK Cell Therapeutics is a South Korean biotechnology company specializing in the development of next-generation Natural Killer (NK) cell therapies for cancer treatment. The company utilizes a proprietary platform technology to mass-produce highly active, high-purity NK cells from umbilical cord blood, facilitating the creation of allogeneic, off-the-shelf therapeutic products. Its lead program, CNK-001, is currently in clinical development for various solid tumors, including non-small cell lung cancer and hepatocellular carcinoma. By combining its expansion technology with chimeric antigen receptor (CAR) engineering, CNK Cell Therapeutics aims to provide potent and accessible immunotherapy options for patients with hard-to-treat malignancies.